Correlation Between Neurobo Pharmaceuticals and Dermata Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Neurobo Pharmaceuticals and Dermata Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurobo Pharmaceuticals and Dermata Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Neurobo Pharmaceuticals and Dermata Therapeutics, you can compare the effects of market volatilities on Neurobo Pharmaceuticals and Dermata Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurobo Pharmaceuticals with a short position of Dermata Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurobo Pharmaceuticals and Dermata Therapeutics.

Diversification Opportunities for Neurobo Pharmaceuticals and Dermata Therapeutics

0.78
  Correlation Coefficient

Poor diversification

The 3 months correlation between Neurobo and Dermata is 0.78. Overlapping area represents the amount of risk that can be diversified away by holding Neurobo Pharmaceuticals and Dermata Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dermata Therapeutics and Neurobo Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurobo Pharmaceuticals are associated (or correlated) with Dermata Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dermata Therapeutics has no effect on the direction of Neurobo Pharmaceuticals i.e., Neurobo Pharmaceuticals and Dermata Therapeutics go up and down completely randomly.

Pair Corralation between Neurobo Pharmaceuticals and Dermata Therapeutics

Given the investment horizon of 90 days Neurobo Pharmaceuticals is expected to under-perform the Dermata Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Neurobo Pharmaceuticals is 1.73 times less risky than Dermata Therapeutics. The stock trades about -0.11 of its potential returns per unit of risk. The Dermata Therapeutics is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest  160.00  in Dermata Therapeutics on September 2, 2024 and sell it today you would lose (47.00) from holding Dermata Therapeutics or give up 29.38% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy98.44%
ValuesDaily Returns

Neurobo Pharmaceuticals  vs.  Dermata Therapeutics

 Performance 
       Timeline  
Neurobo Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Neurobo Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Dermata Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Dermata Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Neurobo Pharmaceuticals and Dermata Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Neurobo Pharmaceuticals and Dermata Therapeutics

The main advantage of trading using opposite Neurobo Pharmaceuticals and Dermata Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurobo Pharmaceuticals position performs unexpectedly, Dermata Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dermata Therapeutics will offset losses from the drop in Dermata Therapeutics' long position.
The idea behind Neurobo Pharmaceuticals and Dermata Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Other Complementary Tools

Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Equity Valuation
Check real value of public entities based on technical and fundamental data
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.